ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Common Equity data on file, last reported at $61.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 73.22% year-over-year to $61.3 million; the trailing twelve-month figure through Mar 2026 stood at $61.3 million (down 73.22% YoY), and the FY2025 full-year result was $114.3 million, down 55.51% from the prior year.
• Common Equity declined to $61.3 million in Q1 2026, from $114.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $272.9 million in Q4 2022 to a low of -$50.2 million in Q3 2022.
• A 5-year average of $162.3 million and a median of $215.2 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 972.7% in 2022, while the deepest fall reached 115.1% in 2022.
• Tracing SPRY's Common Equity over 5 years: stood at $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then gained by 11.28% to $256.8 million in 2024, then slumped by 55.51% to $114.3 million in 2025, then slumped by 46.34% to $61.3 million in 2026.
• Business Quant data shows SPRY's Common Equity at $61.3 million in Q1 2026, $114.3 million in Q4 2025, and $147.7 million in Q3 2025.